Rhythm Pharmaceuticals (RYTM) Gains from Sales and Divestitures (2017 - 2023)
Rhythm Pharmaceuticals (RYTM) reported Gains from Sales and Divestitures of $214837.0 for Q4 2023, up 35.5% year-over-year from $158546.0 in Q4 2022, and up 35.5% quarter-over-quarter from $158546.0 in Q4 2022.
Rhythm Pharmaceuticals (RYTM) Gains from Sales and Divestitures (2017 - 2023) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has 6 years of Gains from Sales and Divestitures data on file, last reported at $214837.0 in Q4 2023.
- Gains from Sales and Divestitures for Q4 2023 came in at $214837.0, up 35.5% year-over-year; the trailing twelve-month figure through Dec 2023 was $214837.0 (up 35.5% YoY), and the FY2023 annual result was $214837.0, up 35.5% from the prior year.
- Gains from Sales and Divestitures grew to $214837.0 in Q4 2023 per RYTM's latest filing, from $158546.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $214837.0 in Q4 2023 and troughed at $25000.0 in Q4 2020.
- A 4-year average of $106491.5 and a median of $93064.5 in 2021 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2021 and 2022: Gains from Sales and Divestitures rose 10.33% in 2021, then jumped 474.8% in 2022.
- A 4-year view of Gains from Sales and Divestitures shows it stood at $25000.0 in 2020, then climbed by 10.33% to $27583.0 in 2021, then jumped by 474.8% to $158546.0 in 2022, then surged by 35.5% to $214837.0 in 2023.
- Business Quant data shows RYTM's Gains from Sales and Divestitures at $214837.0 in Q4 2023, $158546.0 in Q4 2022, and $27583.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Rhythm Pharmaceuticals | 6.59 Bn | 6.25 Bn | 52.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 214,837.00 |
| Dec 31, 2023 | 214,837.00 |
| Dec 31, 2022 | 158,546.00 |
| Dec 31, 2022 | 158,546.00 |
| Dec 31, 2021 | 27,583.00 |
| Dec 31, 2021 | 27,583.00 |
| Dec 31, 2020 | 25,000.00 |
| Dec 31, 2020 | 25,000.00 |
| Dec 31, 2018 | 16,555.00 |
| Dec 31, 2018 | 16,555.00 |
| Dec 31, 2017 | 71,048.00 |
| Dec 31, 2017 | 71,048.00 |